Medicus Pharma (MDCX) announces that it has received “study may proceed” clearance from the U.S. Food and Drug Administration, FDA, to initiate its Phase 2b dose-optimization study of Teverelix, an investigational next generation long-acting GnRH antagonist, in men with advanced prostate cancer, APC.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDCX:
- Medicus Pharma Lowers Teverelix Royalty Burden in Amended LifeArc License
- Medicus announces amendment to LifeArc license improving Teverelix profile
- Medicus Pharma Highlights Positive Teverelix Phase 1 Data and Near-Term SkinJect Milestones
- Medicus Pharma announces clinical data on Teverelix
- Medicus Pharma Ramps Up Partnering Push as Phase 2 SkinJect Data Nears